Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for Prevention of Cancer Therapy-Related Myocardial Injury
NCT05730777Phase 4Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised trial of bifidobacterium bifidum in Cardiotoxicity (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: The decline rate of global longitudinal strain at 6 months. Status: unknown.
02
Drugs
bifidobacterium bifidum
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT05730777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05730777.